Regulation & Compliance
FDA rule removes a device-clearance barrier for federal drug testing
· Source: Federal Register
An FDA rule effective October 6 exempts specified federally regulated drug-testing systems from certain premarket-notification requirements, removing an obstacle to oral-fluid and potential hair-testing programs. It does not, by itself, authorize carriers to begin DOT hair testing or make every oral-fluid collection immediately operational.
Summary and practical context by RoadHouse Recruiting · Reviewed
The FDA action addresses device clearance
The final FDA order exempts certain clinical toxicology test systems used in federal programs from 510(k) premarket notification. Industry groups view that as an important implementation step, but it is one part of a larger federal testing framework.
Carrier testing rules have not instantly changed
DOT guidance still controls which specimens, laboratories and devices may be used in transportation testing. Hair testing is not automatically authorized by this FDA order, and oral-fluid implementation depends on compliant laboratories, devices and DOT requirements.
What employers should do
RoadHouse perspective: continue following current Part 40 instructions and the employer's qualified testing provider. Do not substitute an instant, point-of-collection or hair test for a required DOT test unless DOT formally authorizes that method.
Understanding the update
The FDA rule is in effect, but it removes a regulatory barrier rather than independently activating new DOT testing methods for every employer.
What it means for drivers and carriers
Keep current DOT testing procedures until written DOT and provider guidance confirms an authorized operational change.
Questions to consider
- Has DOT authorized the specific specimen, device and laboratory pathway?
- Has the collection provider updated its written Part 40 procedures?
- Are non-DOT tests clearly separated from federally required tests?
Read the original reporting
This page provides an original summary and practical commentary. The linked source contains the full reporting. Older stories reflect information available on their published dates.
Read the source at Federal Register ↗ (opens in a new tab)